NASD · Healthcare · Biotechnology · USA
Maravai LifeSciences Holdings Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Maravai LifeSciences supplies essential materials and testing solutions for pharmaceutical development across the drug, vaccine, and diagnostic sectors. Operating through TriLink, which produces modified nucleic acids and enzymes, and Cygnus, which detects manufacturing impurities, the company serves biopharmaceutical developers, research institutions, and diagnostics firms. It reaches customers worldwide via direct sales and distributor partners.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Maravai LifeSciences Holdings Inc stock.
Overvalued: intrinsic value $1.17 per share, market price $7.20, margin of safety -515.5% (as of 2026-10-20).
Its through-the-cycle earnings (16.8% median margin), capitalised at 8.3% with no growth, values the shares at $1.17; the price of $7.20 is 515% above that value.
17 more funds hold it; the full list is part of the paid plan.
97 more in this industry show a wider margin of safety.
MRVI is overvalued (as of the 2026-10-20 close). Its through-the-cycle earnings (16.8% median margin), capitalised at 8.3% with no growth, values the shares at $1.17; the price of $7.20 is 515% above that value.
$1.17 per share (as of the 2026-10-20 close), against a market price of $7.20. That is a margin of safety of -515.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.